John Reed, Sanofi R&D chief (Jeff Rumans)
Sanofi flashes more PhIII data on new multiple myeloma drug, setting up battle with Darzalex
Two months after nabbing their first approved cancer drug in a decade, Sanofi announced new late-stage data burnishing the drug’s efficacy in another combination for multiple myeloma.
In a 302-person Phase III trial, investigators combined the new drug, known as Sarclisa, with Amgen’s Kyprolis and showed that the cocktail was more effective than Kyprolis alone. Although Sanofi did not release data, they said the independent review board had stopped it after the combo showed “significantly prolonged progression-free survival.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
